A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).-MedSci.cn

A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).

Ahn, DH; Barzi, A; Ridinger, M; Samuelsz, E; Erlander, MG; Bekaii-Saab, TS; Lenz, HJ

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务